# Specialist Agent Record Draft

## A. Agent and Version

- Repository / branch / commit: `kh4214/MASY1800-ET-Agent-Lab` / `lab4-promethean-classification` / `b3df24d`
- Agent / assignment: Promethean Technology Classification Agent / Lab 4
- Version: 0.3-student
- Purpose: Apply Chapter 11 categorical-barrier and cross-tier transformation logic without changing the frozen common contracts.

## B. Specialist Purpose and Context

The agent distinguishes Incremental, Breakthrough, Potentially Promethean, and Insufficient Evidence. It requires a defensible categorical barrier, a reduction-versus-dissolution finding, separate demonstrated and plausible cross-tier effects, six supporting criteria, strongest evidence for and against, evidence-based forward-looking trend analysis, and a bounded management implication.

## C. Three-Level Finding

- General ET finding: Implantable BCI systems for communication and digital-device control are a **Breakthrough** with moderate confidence. Selected investigational participants demonstrate meaningful bypass of impaired output channels, but broad durable categorical-barrier dissolution across two tiers is not established.
- Application finding: For severe paralysis, communication and computer access directly address the relevant constraint. Results are promising clinical-research evidence, not proof of routine clinical efficacy or human enhancement.
- Organization-specific finding: The large teaching hospital may consider a limited, governed research role; the smaller risk-averse hospital should use referral/monitoring rather than initiate a program. The classification does not change.

## D. Evidence and Testing

- Primary record: `responses/primary_response.json`; contrast record: `responses/contrast_1_response.json`. Both were independently generated in the active Codex GPT-5 session on 2026-10-17 from the rebuilt prompt packets. They were not copied, paraphrased, or derived from the previous local drafts, which remain as `*_pre_independent_run_draft.json` backups.
- Evidence for: FDA implanted-BCI guidance; Metzger et al. (Nature, 2023); NIH summary of 2025 speech work; Card et al. (Nature Medicine, 2026). Full traceable references are embedded in the response records.
- Strongest contrary evidence: very small specialized studies, invasiveness, uncertain durability/generalizability, constrained access, and absent demonstrated broad cross-tier transformation.
- Stable contrast conclusion: technology classification, evidence base, and absence of proven widespread cross-tier impact.
- Changed contrast conclusion: the large hospital could explore a bounded study; the smaller hospital lacks stated infrastructure and should not initiate within three years.
- Preserved failure: `primary_v0_1_schema_failure.json` contains a specialist-only top-level `promethean_criteria` object. It violates the frozen schema's `additionalProperties: false` contract. The bundled validator checks required fields/types but does not enforce that rule, so the incompatibility was identified by direct comparison with `core/output_schema.json` rather than by claiming a bundled-validator failure.
- Revision: version 0.2 maps criteria, tests, evidence for/against, and management boundaries into existing common fields. The independently generated primary and contrast records pass the bundled validator and have no top-level fields outside the frozen schema.
- Reproducibility issue fixed: the first prompt-packet build failed because the frozen Python tool uses the Windows default encoding and could not read typographic quotation marks/en dashes in the editable instructions. The instructions were converted to ASCII punctuation only; both packets then built successfully. The frozen tool was not changed.
- Primary result: Breakthrough, moderate confidence. The model identified a task-specific partial dissolution of the need for reliable bodily output, but did not treat small specialized studies as proof of widespread or multi-tier transformation. It recommended considering only a protocol-bound research partnership.
- Contrast result: Breakthrough, moderate confidence. The technology-level finding stayed evidence-consistent; the smaller hospital's limited research/surgical/support capacity changed the recommendation to no local program, referral/monitoring, and reassessment only after capacity and evidence improve.
- Trend-analysis revision and retest: version 0.3 requires the agent to investigate accessible research, trials, adoption barriers, trajectories, and milestones; distinguish observed trends, evidence-based projections, and speculation; and disclose research-access limits. The prior independent responses are preserved as `*_pre_trend_analysis.json`. Both revised packets were rebuilt and independently executed in the active Codex GPT-5 session on 2026-10-17.
- Revised primary result: Breakthrough, moderate confidence. New evidence included a 2026 single-participant report of nearly two years of independent home speech/cursor use. The model treated this as an observed trajectory toward practical assistive use, while requiring multi-site replication, standardized outcomes, durability, and accessible delivery before reclassification.
- Revised contrast result: Breakthrough, moderate confidence. The technology classification remained stable. The smaller hospital should still not initiate a local program; trend evidence supports monitoring/referral, not lower readiness requirements.
- Comparison with previous test: classification and organization-specific recommendations did not change. The revised runs improved specificity by identifying the home-use result as observed evidence, identifying FDA/NIH outcome-measurement work as a translation barrier, and defining conditional near-term milestones rather than generic uncertainty.
- Remaining limitation: these are genuine model executions, but they remain one model's responses to two hypothetical cases. Schema validation checks structure, not clinical accuracy. Device-specific safety, cost, patient eligibility, and real site capacity require independent expert review.

## E. Independent Judgment and Handoff

**REQUIRES STUDENT REVIEW:** See `independent_professional_judgment.md` before submitting. The next team should preserve the fixed schema, three-level separation, and explicit uncertainty about future effects; see `team_handoff.md`.

## AI and Verification Note

Codex rebuilt each packet, then generated each response independently in the active Codex GPT-5 session. The earlier responses were preserved before each rerun. Consequential BCI claims and trend evidence were checked against accessed FDA guidance/workshop material, NIH material, Nature/PMC search results, and PubMed. The student must independently review source fit and the professional judgment before submission.
